恩替卡韦联合益生菌治疗失代偿期乙肝肝硬化疗效观察  

Treatment Effect of Entecavir Combined with Probiotics on Hepatitis B Patients with Decompensated cirrhosis

作　　者：何伟锋[1] 谭斌[2] 

机构地区：[1]惠州市第一人民医院消化内科,广东惠州516003 [2]惠州市中心人民医院肝病科,广东惠州516001

出　　处：《亚太传统医药》2013年第6期153-154,共2页Asia-Pacific Traditional Medicine

基　　金：惠州市科技计划项目(2011Y093);广东省医学科研基金项目(B2010313)

摘　　要：目的:探讨核苷类联合益生菌治疗失代偿期乙肝肝硬化患者的疗效。方法:将70例失代偿期乙肝肝硬化患者随机分治疗组及对照组,在综合治疗基础上,治疗组应用恩替卡韦及益生菌,对照组仅用恩替卡韦,疗程1年。治疗前后观察两组生化指标、病毒指标、自发性细菌性腹膜炎发生率及预后指标。结果:治疗组生化指标、血清内毒素指标、自发性细菌性腹膜炎发生率优于对照组,而病毒复制及死亡率情况,两组无差异。结论:恩替卡韦联合益生菌在治疗乙型肝炎失代偿期肝硬化方面有较好疗效。Objective： To investigate efficacy of entecavir combined with probiotics on Hepatitis B Patients with Decompensated cirrhosis. Methods：70 patients with decompensated HBV-related cirrhosis were randomly divided into treatment group and control group. On the basis of the comprehensive treatment, the treatment group were used well for entecavir and probiotics, but the con- trol group only used entecavir. After 1 years. Observed biochemical index, viral markers, spontaneous bacterial peritonitis incidence and prognostic index before and after treatment in two groups. Results：In treatment group, the serum endotoxin index, biochemical index of spontaneous bacterial peritonitis incidence rate were lower than control group, but the virus replication and mortality rate, no difference between two groups. Conclusion ： Treatment effect of entecavir combined with probiotics on decompensated cirrhosis due to hepatitis B was better.

关 键 词：恩替卡韦 益生菌 肝硬化 

分 类 号：R575.2[医药卫生—消化系统]